An observational study in Gynecologic Disease, sponsored by University of Southern California. Recruiting at 1 site in United States. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-08-06.
Sponsored by University of Southern California · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 31 studies in Genital Diseases, Female with a site in United States — 5 open to participants now, 7 under way, none of them phase 3. Genital Diseases, Female · United States.
Among the 31 studies in Genital Diseases, Female with a site in United States, this one is one of 2 that started in 2026, is one of 7 observational ones, and was the 30th registered.
161 studies on the registry are indexed under Genital Diseases, Female; 31 are open to participants now.
Browse Genital Diseases, Female studies →5 of the 31 studies in Genital Diseases, Female with a site in United States are open now. Recruiting first, the newest first:
Nanopath, Inc · Sites in United States
Ages 18+ · Women only
Stanford University · Sites in United States
Ages 18+
Pfizer · Sites in United States, Puerto Rico
Ages 18+ · Women only
University of Colorado, Denver · Sites in United States
Ages 9–17 · Women only
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 21 Genital Diseases, Female studies recruiting now, 10 (48%) set no upper age limit and 11 (52%) stop at 75 or younger; 3 take children under 18; 4 take healthy volunteers.
This study: 18 Years and older · female · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
31 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 2 · Phase 2 3 · Phase 3 3 · Phase 4 3
First in 2003; this study’s year is marked. 2 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 48 is below the median of 200 across 37 observational studies indexed under Genital Diseases, Female.
Median enrollment 50 across the 24 interventional studies, 48 across the 7 observational. Of the 19 that completed or were terminated, 8 (42%) have results posted.
This tab as a report to print or save as PDF → With an account.
11 of 31 have an industry lead sponsor. The 10 most frequent:
University of Southern California is the lead sponsor of 792 studies on the registry; 137 are open to participants now.
Of its 70 completed or terminated interventional studies of FDA-regulated products, 32 (46%) have results posted.
University of Southern California has 1 study filed under Genital Diseases, Female — fewer than ten, so there is no comparison to draw.
4 of the studies in Genital Diseases, Female with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07607470Nanopath, IncLarge Algorithm Setting and Validation Study | 2026-12 |
| NCT07044505Stanford UniversityMolecular and Cellular Profiling of Uterine Lavage Collected During Gynecologic Surgery | 2026-12 |
| NCT06611501Boston Children's HospitalGlycemic Regulation as Endometriosis Adjunct Treatment | 2027-01 |
| NCT07279571University of Southern CaliforniaGYN-AIDE: Gynecologic Oncology Navigation Through AI-Driven Education | 2027-06-09 |
Add all 4 to your calendar (.ics) → With an account.
Among the 31 studies in Genital Diseases, Female with a site in United States, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This study seeks to understand how endometrial cancer patients get medical information about cancer care and their satisfaction with those health-seeking methods. It also assesses patient interest in using an artificial intelligence educational resource.
AIM 1: Evaluate use of an AI chatbot for HPV vaccine counseling:
PRIMARY OBJECTIVE:
I. To determine patient satisfaction with using an AI chatbot for HPV vaccine counseling.
SECONDARY OBJECTIVE:
I. To understand how patients currently obtain information about cancer care, vaccines, and artificial intelligence.
II. To describe patient experience with the AI-chatbot for vaccine counseling.
AIM 2: Increase rates of HPV vaccine uptake:
PRIMARY OBJECTIVE:
I. To evaluate if implementation of an AI chatbot for HPV vaccine counseling can affect the HPV vaccination rate of new patients served in the gynecologic oncology clinic.
OUTLINE: This is an observational study.
Patients complete a survey on study.
Patients of the LA General gynecologic oncology clinic who meet the eligibility criteria.
AI-chatbot Evaluation (Aim 1):
Inclusion Criteria:
Exclusion Criteria:
HPV vaccination rate (Aim 2):
Inclusion Criteria:
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Patients complete a survey on study.
Other: Non-Interventional Study
Non-interventional study
Also known as: Non-Interventional Observational Study, Noninterventional (Observational) Study
Patient Satisfaction Scores
Patients will complete a survey to assess their satisfaction with using an AI chatbot for HPV vaccine counseling.
Time frame: Up to 1 year
HPV Vaccination Rate
HPV vaccination rate for patients who received the HPV vaccine counseling with the AI-chatbot
Time frame: Up to 1 year
Demographics of patients
Will be analyzed using a qualitative description of the demographics of patients involved in this specific study.
Time frame: Up to 1 year
Started Jun 2026 (actual). Primary completion is estimated for Jun 2027, 11 months after the start.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
No contact was published for this record. The registry link below has the sponsor’s details.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
University of Southern California →